InVivo Therapeutics Holdings Corp. ( NVIV) Stock. Should you Buy or Sell? $ 5.92
0.41 (6.48 %)
InVivo Therapeutics Holdings Corp. Analysis
Updated on 10-09-2022| Symbol | NVIV |
| Price | $5.92 |
| Beta | 1.306 |
| Volume Avg. | $731.9 thousand |
| Market Cap | $8.24 M |
| 52 Week Range | $3.5 - $17.75 |
InVivo Therapeutics Holdings Corp. opened the day at $5.92 which is +'6.48 % on yesterday's close. InVivo Therapeutics Holdings Corp. has a 52 week high of $17.75 and 52 week low of $3.5, which is a difference of $14.25. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $8.24 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy InVivo Therapeutics Holdings Corp. for $8.24 M, it would take 15 years to get your money back. InVivo Therapeutics Holdings Corp. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
InVivo Therapeutics Holdings Corp. Stock Forecast - Is InVivo Therapeutics Holdings Corp. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Sell | |
| ROA Score | Sell | |
| DE Score | Neutral | |
| PE Score | Sell | |
| PB Score | Neutral | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -0.462 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.000 |
Valuing InVivo Therapeutics Holdings Corp.
| Price Book Value Ratio | 0.639 | Price To Book Ratio | 0.639 |
| Price To Sales Ratio | 0.000 | Price Earnings Ratio | -0.462 |
How liquid is InVivo Therapeutics Holdings Corp.
| Current Ratio | 5.641 |
| Quick Ratio | 5.413 |
Debt
| Debt Ratio | 0.203 | Debt Equity Ratio | 0.254 |
| Long Term Debt To Capitalization | 0.056 | Total Debt To Capitalization | 0.081 |
Latest news about InVivo Therapeutics Holdings Corp.
This sector is always a risky area to gamble in. If you have the stomach for it, however, these biotech stocks could see massive gains.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has enrolled 15 patients with acute spinal cord injury into the INSPIRE 2.0 Study, or 75% of the total 20-patient enrollment target for the study. The INSPIRE 2.0 study is a randomized, controlled trial (20-patient, 10 subjects in each study arm), that is designed
Are these the best biotech penny stocks to watch in 2021? The post 3 Biotech Penny Stocks That You Need to Know About In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny Stocks For Your Watch List In July The post Best Penny Stocks To Watch For July 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
The stock price of Invivo Therapeutics Holdings Corp (NASDAQ: NVIV) increased by over 36% during intraday trading. This is why it happened.
About InVivo Therapeutics Holdings Corp.
Description :
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
